By:
On:
In: Fair company, Stock analysis
Tagged:
With: 0 Comments

 

Company name China Biologic Products Holdings Inc
Stock ticker CBPO
Live stock price [stckqut]CBPO[/stckqut]
P/E compared to competitors Fair

 

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Fair
EPS growth Good
P/E growth Poor
EBIT growth Good
Price growth Good
R&D growth Fair
Income growth Good
Assets growth Good
Return on Assets growth Poor
Income / Rev growth Fair
TWCA Plus Good
Standard TWCA Good
Weighted ann. stock price increase Poor

 

ANALYSIS

Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $169.48
Target stock price (averages with growth) $120.38
Target stock price (averages with no growth) $119.75
Target stock price (manual assumptions) $128.17

 

The following company description is from Reuters: https://finance.yahoo.com/quote/cbpo/profile?p=cbpo

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People’s Republic of China.

 

Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in China Biologic Products Holdings Inc as long as the price is correct and the indicators that I describe in my book The Confident Investor are favorable. Most of the fundamentals of this company are good but there are some concerns. I am removing China Biologic from my Watch List due to its recent stock performance and the current climate of reducing the importance of companies from China in western markets. This will make room for stocks that are higher performing.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of China Biologic Products Holdings Inc calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $109.64
  • Growth: 0.1647
  • Current EPS (TTM): $3.64833333333333
  • P/E: 26.3983823385159
  • Future EPS Calc: $7.81
  • Future Stock Price Calc: $206.41
  • Target stock price: $128.16

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

 

Company name Align Technology, Inc.
Stock ticker ALGN
Live stock price [stckqut]ALGN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good
Price growth Good
R&D growth Good
Income growth Good
Assets growth Good
Return on Assets growth Poor
Income / Rev growth Poor
TWCA Plus Good
Standard TWCA Good
Weighted ann. stock price increase Good


ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $407.56
Target stock price (averages with growth) $203.07
Target stock price (averages with no growth) $150.75
Target stock price (manual assumptions) $405.34

The following company description is from Reuters: https://finance.yahoo.com/quote/algn/profile?p=algn

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign Comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment’s non-comprehensive products comprise Invisalign Moderate, Lite and Express packages, and Invisalign Go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero Scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers; computer-aided design/computer-aided manufacturing services and ancillary products, such as disposable sleeves for the wand; and iTero applications and tools. The company sells its products in the United States, the Netherlands, China, and internationally. Align Technology, Inc. was founded in 1997 and is headquartered in San Jose, California.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Align Technology, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Align Technology, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $263.79
  • Growth: 0.2
  • Current EPS (TTM): $23.85
  • P/E: 11
  • Future EPS Calc: $59.34
  • Future Stock Price Calc: $652.81
  • Target stock price: $405.34

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $429.08
Target stock price (averages with growth) $578.79
Target stock price (averages with no growth) $393.15
Target stock price (manual assumptions) $427.13

The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/ilmn

Illumina, Inc. (Illumina), incorporated on May 16, 2000, is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. GRAIL is engaged in developing a blood test for early-stage cancer detection. Helix was established to enable individuals to explore their genetic information by providing sequencing and database services for consumers through third-party partners.

The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company offers its products and services to various customers, including genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The Company’s products and services enable the adoption of genomic solutions in research and clinical settings. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing. The Company’s technology enables NIPT for early identification of fetal chromosomal abnormalities by analyzing cell-free deoxyribonucleic acid (DNA) in maternal blood. Its preimplantation genetic screening solution is used with in vitro fertilization (IVF) to determine, before implantation, whether an embryo has an abnormal number of chromosomes. Its preimplantation genetic diagnosis technology determines which embryos are free from gene variants associated with genetic diseases.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Illumina, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $277.75
  • Growth: 0.2
  • Current EPS (TTM): $4.85
  • P/E: 57
  • Future EPS Calc: $12.06
  • Future Stock Price Calc: $687.89
  • Target stock price: $427.12

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name China Biologic Products Holdings, Inc.
Stock ticker CBPO
Live stock price [stckqut]CBPO[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Fair

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $130.58
Target stock price (averages with growth) $135.88
Target stock price (averages with no growth) $92.3
Target stock price (manual assumptions) $121.87

 

The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/cbpo

China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing, and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.

The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC). The Company offers human albumin for the treatment of shock caused by blood loss trauma or burn, raised intracranial pressure caused by hydrocephalus or trauma, edema or ascites caused by hepatocirrhosis and nephropathy, prevention and treatment of low-density-lipoproteinemia, and neonatal hyperbilirubinemia. It offers human immunoglobulin and IVIG for the treatment of original immunoglobulin deficiency, such as X chain low immunoglobulin, familiar variable immune deficiency, immunoglobulin G secondary deficiency, secondary immunoglobulin deficiency, such as infection and newborn sepsis, and auto-immune deficiency diseases, such as original thrombocytopenia purpura or kawasaki disease. It offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis. It offers human rabies immunoglobulin for passive immunity from bites or claws by rabies or other infected animals. It offers human tetanus immunoglobulin for the prevention and therapy of tetanus. It offers placenta polypeptide for the treatment for cell immunity deficiency diseases, viral infection and leucopenia caused by various reasons, and also in postoperative healing. It offers Factor VIII for the treatment for coagulopathies, such as hemophilia A and increased concentration of coagulation factor VIII. It offers PCC for the treatment of congenital and acquired clotting factor II, VII, IX, X deficiency, such as Hemophilia B, excessive anticoagulant, and vitamin K deficiency.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in China Biologic Products Holdings, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of China Biologic Products Holdings, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $84.52
  • Growth: 0.15
  • Current EPS (TTM): $2.38
  • P/E: 41
  • Future EPS Calc: $4.78
  • Future Stock Price Calc: $196.26
  • Target stock price: $121.86

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $344.83
Target stock price (averages with growth) $451.51
Target stock price (averages with no growth) $306.69
Target stock price (manual assumptions) $303.03

 

The following company description is from Google Finance: https://finance.google.com/finance?q=ilmn

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable. I am adding Illumina to my Watch List.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Illumina, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $223.37
  • Growth: 0.17
  • Current EPS (TTM): $5.3
  • P/E: 42
  • Future EPS Calc: $11.61
  • Future Stock Price Calc: $488.03
  • Target stock price: $303.03

[/s2If]
I hope that this makes you a Confident Investor.